Regulation of neurotensin receptor mRNA expression by neuroleptics in the rat midbrain dopaminergic neurons

T. Cho, M. Yamada, M. Yamada, E. Richelson

Research output: Contribution to journalArticle

Abstract

The tridecapeptide neurotensin is a putative neurotransmitter in the central nervous system. Studies with experimental animals show that neurotensin interacts with dopaminergic neurons. And it is proposed that neurotensin is involved in the pathophysiology of some neuropsychiatric disorders thought to be related to malfunction of the dopaminergic system. The receptor for neurotensin has been molecularly cloned from rat brain. Uhl and Kuhar reported that the density of this receptor is increased in substantia nigra of humans treated chronically with typical neuroleptics. In this study, we found that two weeks of haloperidol (1 mg/kg/day), but not clozapine (20 mg/kg/day), chlorpromazine (10 mg/kg/day), thioridazine (10 mg/kg/day) increased neurotensin receptor mRNA levels in the rat substantia nigra and ventral tegmental area. We have examined the expression of neurotensin receptor mRNA using in situ hybridization techniques with an 35S-labeled antisense RNA probe (302 bp) complementary to this receptor cDNA. Clinically, haloperidol treatment lead to a high incidence of extrapyramidal side effects. The mechanisms responsible for their differential incidence of extrapyramidal side effect are uncertain. Neurotensin and its signal transduction system may, in part, contribute to the pathophysiology of the extrapyramidal side effects from chronic haloperidol treatment by affecting dopaminergic system.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalResearch Communications in Biological Psychology and Psychiatry
Volume20
Issue number1-2
StatePublished - 1995

Fingerprint

Neurotensin Receptors
Neurotensin
Dopaminergic Neurons
Mesencephalon
Antipsychotic Agents
Haloperidol
Messenger RNA
Substantia Nigra
Thioridazine
RNA Probes
Antisense RNA
Ventral Tegmental Area
Clozapine
Incidence
Chlorpromazine
In Situ Hybridization
Neurotransmitter Agents
Signal Transduction
Central Nervous System
Complementary DNA

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Regulation of neurotensin receptor mRNA expression by neuroleptics in the rat midbrain dopaminergic neurons. / Cho, T.; Yamada, M.; Yamada, M.; Richelson, E.

In: Research Communications in Biological Psychology and Psychiatry, Vol. 20, No. 1-2, 1995, p. 1-5.

Research output: Contribution to journalArticle

@article{e8de3447e9f74b07b4ed400df2ffd11b,
title = "Regulation of neurotensin receptor mRNA expression by neuroleptics in the rat midbrain dopaminergic neurons",
abstract = "The tridecapeptide neurotensin is a putative neurotransmitter in the central nervous system. Studies with experimental animals show that neurotensin interacts with dopaminergic neurons. And it is proposed that neurotensin is involved in the pathophysiology of some neuropsychiatric disorders thought to be related to malfunction of the dopaminergic system. The receptor for neurotensin has been molecularly cloned from rat brain. Uhl and Kuhar reported that the density of this receptor is increased in substantia nigra of humans treated chronically with typical neuroleptics. In this study, we found that two weeks of haloperidol (1 mg/kg/day), but not clozapine (20 mg/kg/day), chlorpromazine (10 mg/kg/day), thioridazine (10 mg/kg/day) increased neurotensin receptor mRNA levels in the rat substantia nigra and ventral tegmental area. We have examined the expression of neurotensin receptor mRNA using in situ hybridization techniques with an 35S-labeled antisense RNA probe (302 bp) complementary to this receptor cDNA. Clinically, haloperidol treatment lead to a high incidence of extrapyramidal side effects. The mechanisms responsible for their differential incidence of extrapyramidal side effect are uncertain. Neurotensin and its signal transduction system may, in part, contribute to the pathophysiology of the extrapyramidal side effects from chronic haloperidol treatment by affecting dopaminergic system.",
author = "T. Cho and M. Yamada and M. Yamada and E. Richelson",
year = "1995",
language = "English (US)",
volume = "20",
pages = "1--5",
journal = "Research Communications in Psychology, Psychiatry and Behavior",
issn = "0362-2428",
publisher = "PJD Publications Ltd",
number = "1-2",

}

TY - JOUR

T1 - Regulation of neurotensin receptor mRNA expression by neuroleptics in the rat midbrain dopaminergic neurons

AU - Cho, T.

AU - Yamada, M.

AU - Yamada, M.

AU - Richelson, E.

PY - 1995

Y1 - 1995

N2 - The tridecapeptide neurotensin is a putative neurotransmitter in the central nervous system. Studies with experimental animals show that neurotensin interacts with dopaminergic neurons. And it is proposed that neurotensin is involved in the pathophysiology of some neuropsychiatric disorders thought to be related to malfunction of the dopaminergic system. The receptor for neurotensin has been molecularly cloned from rat brain. Uhl and Kuhar reported that the density of this receptor is increased in substantia nigra of humans treated chronically with typical neuroleptics. In this study, we found that two weeks of haloperidol (1 mg/kg/day), but not clozapine (20 mg/kg/day), chlorpromazine (10 mg/kg/day), thioridazine (10 mg/kg/day) increased neurotensin receptor mRNA levels in the rat substantia nigra and ventral tegmental area. We have examined the expression of neurotensin receptor mRNA using in situ hybridization techniques with an 35S-labeled antisense RNA probe (302 bp) complementary to this receptor cDNA. Clinically, haloperidol treatment lead to a high incidence of extrapyramidal side effects. The mechanisms responsible for their differential incidence of extrapyramidal side effect are uncertain. Neurotensin and its signal transduction system may, in part, contribute to the pathophysiology of the extrapyramidal side effects from chronic haloperidol treatment by affecting dopaminergic system.

AB - The tridecapeptide neurotensin is a putative neurotransmitter in the central nervous system. Studies with experimental animals show that neurotensin interacts with dopaminergic neurons. And it is proposed that neurotensin is involved in the pathophysiology of some neuropsychiatric disorders thought to be related to malfunction of the dopaminergic system. The receptor for neurotensin has been molecularly cloned from rat brain. Uhl and Kuhar reported that the density of this receptor is increased in substantia nigra of humans treated chronically with typical neuroleptics. In this study, we found that two weeks of haloperidol (1 mg/kg/day), but not clozapine (20 mg/kg/day), chlorpromazine (10 mg/kg/day), thioridazine (10 mg/kg/day) increased neurotensin receptor mRNA levels in the rat substantia nigra and ventral tegmental area. We have examined the expression of neurotensin receptor mRNA using in situ hybridization techniques with an 35S-labeled antisense RNA probe (302 bp) complementary to this receptor cDNA. Clinically, haloperidol treatment lead to a high incidence of extrapyramidal side effects. The mechanisms responsible for their differential incidence of extrapyramidal side effect are uncertain. Neurotensin and its signal transduction system may, in part, contribute to the pathophysiology of the extrapyramidal side effects from chronic haloperidol treatment by affecting dopaminergic system.

UR - http://www.scopus.com/inward/record.url?scp=0028874930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028874930&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028874930

VL - 20

SP - 1

EP - 5

JO - Research Communications in Psychology, Psychiatry and Behavior

JF - Research Communications in Psychology, Psychiatry and Behavior

SN - 0362-2428

IS - 1-2

ER -